Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin

INTRODUCTION: Treatment with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, which target the incretin axis, has the potential to improve glycemic control in type 2 diabetes patients without the weight gain associated with traditional therapies. To evaluate the relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezquita Raya, Pedro, Pérez, Antonio, Ramírez de Arellano, Antonio, Briones, Teresa, Hunt, Barnaby, Valentine, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889333/
https://www.ncbi.nlm.nih.gov/pubmed/24132613
http://dx.doi.org/10.1007/s13300-013-0044-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889333/
https://www.ncbi.nlm.nih.gov/pubmed/24132613
http://dx.doi.org/10.1007/s13300-013-0044-9

Ejemplares similares